LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lyka Labs Ltd has submitted its Annual Secretarial Compliance Report for FY2024-25, certified by Practicing Company Secretary Kaushal Doshi & Associates. The report confirms full compliance with SEBI LODR Regulations, secretarial standards, insider trading norms, and all other applicable SEBI regulations, with no deviations, penalties, or actions taken by SEBI or stock exchanges during the year. Notable corporate actions during the year included the allotment of 26 lakh equity shares of Rs. 10 each at a Rs. 129.50 premium to promoter group member Ipca Laboratories Ltd upon conversion of warrants on 16th April 2024. The company also filed a fresh scheme of amalgamation between Lyka Exports Ltd and Lyka Labs Ltd with NCLT Ahmedabad, and held shareholder and creditor meetings as directed on 23rd January 2025.
This is a routine compliance filing confirming good corporate governance with no regulatory issues, which is neutral to positive for shareholders. The warrant conversion by Ipca Laboratories strengthens the promoter group's stake, while the ongoing amalgamation process with Lyka Exports could streamline the group structure.